Antipsychotics in treatment of eating disorders patient: A study with risperidone;Uso de antipsicóticos en el tratamiento de pacientes con trastorno de la conducta alimentaria: Estudio con risperidona

Actas Espanolas de Psiquiatria

Volumn 33, Issue 1, 2005, Pages 33-40

  Beato Fernandez L ^a,b   Rodriguez Cano T ^a  

^a Unidad de Trastornos Alimentarios   (Spain)

^b NONE   (Spain)

Author keywords

Anorexia nervosa; Antipsychotic drugs; Bulimia nervosa; Eating disorders; Risperidone; Treatment

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; EATING DISORDER; FEMALE; HUMAN; INTERVIEW; PSYCHOLOGIC ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; ANTIPSYCHOTIC AGENTS; EATING DISORDERS; FEMALE; HUMANS; PROSPECTIVE STUDIES; RISPERIDONE;

EID: 16244423304     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Trastornos del comportamiento alimentario. Criterios de ordenación de recursos y actividades. Madrid: Publicaciones del Insalud, 2000; p. 1.
2. Kaye WH, Strober M. Serotonin: implications for the etiology & treatment of eating disorders. Eat Dis Rev 1999;10 (3):1-3.
3. Barry VC, Klawans HL. On the role of dopamine in the pathophysiology of anorexia nervosa. J Neural Transm 1976;38:107-22.
4. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3-16.
5. Towell A, Muscat R, Willner P. Behavioural microanalysis of the role of dopamine in amphetamine anorexia. Pharmacol Biochem Behav 1988;30:641-8.
6. Crisp JH. A treatment regime for anorexia nervosa. Br J Psychiatry 1996;112:505-12.
7. Dally P, Sargant W. Treatment and outcome of anorexia nervosa. Br Med J 1966;2:793-5.
8. Walsh T, Devlin M. The phamacologic treatment of eating disorders. Psychiat Clin North Am 1992;15:1.
9. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. Acta Psychiatr Scand 1982;66:445-50.
10. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984;144:288-92.
11. Hoffman L, Halmi D. Psychopharmacology in the treatment of anorexia nervosa and bulimia nervosa. Psychiatr Clin North Am 1993;16(4):767-78.
12. Trastornos del Comportamiento Alimentario. Criterios de ordenación de recursos y actividades. Madrid: Publicaciones del Insalud, 2000; p. 44.
13. a ed., 1999.
14. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behavior. J Affective Dis 1982;28:325-38.
15. Blum K, Cull JG, Braverman ER. Reward deficiency syndrome. American Scientist 1996;84:132-45.
16. Jimerson D, Lesem M, Kaye W, Brewerton T. Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry 1992;49:132-8.
17. Condon JT. Long-term neuroleptic therapy in chronic anorexia nervosa complicated by tardive dyskinesia. A case report. Acta Psychiatr Scand 1986;73(2):203-6.
18. Rohrbaugh RM, Siegal AP. Reversible anorexia and rapid weight loss associated with neuroleptic administration in Alzheimer's disease. J Geriatr Psychiatry Neurol 1989;2(1):45-7.
19. Rubio Larrosa V, Pérez Urdaniz A, Granada López JM. Risperidona y trastorno límite de personalidad. Póster presentado en el I Congreso Nacional de Trastornos de Personalidad. Zaragoza, 1998.
20. McDougle CJ, Epperson CN, Pelton GH. A Double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801.
21. McDougle CJ, Goodman WK, Price LH. Neuroieptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-4.
22. McDougle CJ, Goodman WK, Leckman JF. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-8.
23. Ravizza L, Barzega G, Bellin S. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996;32:677-82.
24. Stein DJ, Bouwer MB, Hawkridge S. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-22.
25. Crisp AH. The possible significance of some behavioral correlates of weight and carbohydrate intake. J Psychosom Res 1967;11:117.
26. Rastan Nm, Gillberg C. Anorexia nervosa 6 years after onset: II. Comorbid psychiatric problems. Compr Psychiatry 1995;36:70.
27. Halmi KA, Eckert E, Marchi P. Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch Gen Psychiatry 1991;48:7-12.
28. Mitchell JE, Specker SM. Comorbidity and medical complications of bulimia nervosa. J Clin Psychiatry 1991;52:13.
29. Braun DL, Sunday SR, Halmi KA. Psychiatric comorbidity with eating disorders. Psychol Med 1994;24:859.
30. Balcioglu A, Wurtman RJ. Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. Int J Obes Relat Metab Disor 1998;22:325-8.
31. Martel P, Fantino M. Mesolimbic dopaminergic system activity as a function for food reward: a microdialysis study. Pharmacol Biochem Behav 1996;53:221-6.
32. Hoebel BG. Brain neurotransmitters in food and drug award. Am J Clin Nutr 1985;42(Suppl. 5):S1133-50.
33. Bassareo V, Di Chiara G. Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/ core compartments. Neuroscience 1999;89:637-41.
34. Pontieri FE, Tanda G, Orzi G, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382:255-77.
35. Leibowitz SF. Opioids and food selection. En: Morgan PG, Pankse PP, editores. Handbook of the Hypothalamus. New York: Marcel Dekker, 1982;3:299-437.
36. Heffner TG, Hartman JA, Seiden LS. Dopamine turnover in feeding. Science 1986;208:1168-70.
37. Wang GJ, Volkow N, Logan J, Pappas NR. Brain dopamine and obesity. Lancet 2001;357:354-7.
38. Wise RA, Spindler J, DWit H, Gerber GJ. Sub-stimulation behaviors. Science 1978;201:262-4.
39. Glimcher P, Margolin D. Dopamine pathways. Brain Res 1986;266:348-52.
40. Halmi KA, Owen WP, Lasley E, Stokes P. Dopaminergic regulation in anorexia nervosa. Int J Eating Disord 1983;21:192-233.
41. Jimerson DC, Lessem Md, Kaye WH. Low serotonin and dopamine metabolite concentrations in cerebral spinal fluid from bulimic patients with frequent binge episodes. Arch Gen Psychiatry 1992;49:132-8.
42. Kaplan AS, Garfinkel PE, Walsh FC. Clonidine challenge test in bulimia nervosa. Int J Eating Disord 1989;8:425-35.
43. Stahl SM. Neuropharmacology of obesity: my receptors made me do it. J Clin Psychiatry 1998;59:447-8.
44. Curzon G, Gibson EL. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 1998;18:21-5.
45. Grof S. Critical variables in LSD therapy. En: LSD Psychotherapy. Pomona: Hunter House, 1980; p. 47.
46. Masters REL, Houston J. Experiencing the body and body image. En: Masters REL, Houston J, editores. The Varieties of Psychedelic Experience. New York: Dell Publishing, 1966; p. 67.
47. Goldberg SC, Eckert ED, Halmi DA, Casper RC. Effects of cyproheptadine on symptoms and attitudes in anorexia nervosa. Arch Gen Psychiatry 1980;37:1083.
48. Goldbloom DS, Olmsted MP. Pharmacotherapy of bulimia nervosa with fluoxetine: assessment of clinically significant attitudinal change. Am J Psychiatry 1993;50:770-4.
49. Allen A, Hollander E. Body dysmorphic disorder. Psychiatr Clin North Am 2000;23(3):617-28.
50. Schotte A, Janssen PMF, Megens AAHP, Leysen JE. Occupancy of Central neurotransmitter receptors by risperidone, clozapine and haloperidol measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191-202.
51. Blundell JE, Hill AJ. Dexfenfluramine and appetite in humans. Int J Obesity 1992;16:S51-9.
52. Liebowitz SF. The role of serotonin in eating disorders. Drugs 1990;39:895-903.
53. La Via M, Gray N, Kaye W. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000;27:363-6.
54. Kraus T, Haack M, Schuld A. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-4.
55. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington: American Psychiatric Association, 1994.
56. First M, Spitzer R, Gibbon M, Williams JB. Structured clinical interview for DSM-IV (SCID-I). American Psychiatric Press, Inc. Versión española publicada por Editorial Masson, 1999.
57. Loranger A, Sartorius N, Andreoli A, Berger P, et al. The International Personality Disorder Examination. The World Health Organization/Alcohol, Drug Abuse and Mental Health Administration International pilot study of personality disorders. Arch Gen Psychiatry 1994;51(3):215-24.
58. Guy W. Early Clinical Drug Evaluation (ECDEU) assessment manual. Rockville: National Institute Mental Health, 1976.
59. Norusis MJ. SPSS for windows: release 10.0. Chicago: SPSS Inc, 1999.
60. Grossman SP. Eating behavior, the biology of motivation. Ann Rev Psychol 1979;30:209-42.